Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 7 de 7
Filter
Add more filters










Database
Language
Publication year range
1.
Histopathology ; 79(5): 690-699, 2021 Nov.
Article in English | MEDLINE | ID: mdl-33872400

ABSTRACT

AIMS: Screening all patients newly diagnosed with colorectal cancer (CRC) for possible Lynch syndrome (LS) has been recommended in the United Kingdom since the National Institute for Health and Care Excellence (NICE) released new diagnostics guidance in February 2017. We sought to validate the NICE screening pathway through a prospective regional programme throughout a 5.2-million population during a 2-year period. METHODS AND RESULTS: Pathology departments at 14 hospital trusts in the Yorkshire and Humber region of the United Kingdom were invited to refer material from patients with newly diagnosed CRC aged 50 years or over between 1 April 2017 and 31 March 2019 for LS screening. Testing consisted of immunohistochemistry for MLH1, PMS2, MSH2 and MSH6 followed by BRAF mutation analysis ± MLH1 promoter methylation testing in cases showing MLH1 loss. A total of 3141 individual specimens were submitted for testing from 12 departments consisting of 3061 unique tumours and 2791 prospectively acquired patients with CRC. Defective mismatch repair (dMMR) was observed in 15% of cases. In cases showing MLH1 loss, 76% contained a detectable BRAF mutation and, of the remainder, 77% showed MLH1 promoter hypermethylation. Of the patients included in the final analysis, 81 (2.9%) had an indication for germline testing. CONCLUSION: LS screening using the NICE diagnostics guidance pathway is deliverable at scale identifying significant numbers of patients with dMMR. This information is used to refer patients to regional clinical genetics services in addition to informing treatment pathways including the use of adjuvant/neoadjuvant chemotherapy and immunotherapy.


Subject(s)
Colorectal Neoplasms, Hereditary Nonpolyposis/diagnosis , Early Detection of Cancer/methods , Genetic Testing/methods , Adult , Aged , Biomarkers, Tumor/genetics , Colorectal Neoplasms/diagnosis , Colorectal Neoplasms/genetics , Colorectal Neoplasms, Hereditary Nonpolyposis/genetics , DNA Methylation , DNA Mismatch Repair/genetics , Female , Genetic Predisposition to Disease , Humans , Immunohistochemistry , Male , Middle Aged , MutL Protein Homolog 1/genetics , Mutation , Prospective Studies , Proto-Oncogene Proteins B-raf/genetics , United Kingdom
2.
BMJ Open ; 9(11): e030618, 2019 11 26.
Article in English | MEDLINE | ID: mdl-31772088

ABSTRACT

INTRODUCTION: Although colorectal cancer outcomes in England are improving, they remain poorer than many comparable countries. Yorkshire Cancer Research has, therefore, established a Bowel Cancer Improvement Programme (YCR BCIP) to improve colorectal cancer outcomes within Yorkshire and Humber, a region representative of the nation. It aims to do this by quantifying variation in practice, engaging with the colorectal multidisciplinary teams (MDTs) to understand this and developing educational interventions to minimise it and improve outcomes. METHODS AND ANALYSIS: Initially, routine health datasets will be used to quantify variation in the demographics, management and outcomes of patients across the Yorkshire and Humber region and results presented to MDTs. The YCR BCIP is seeking to supplement these existing data with patient-reported health-related quality of life information (patient-reported outcome measures, PROMs) and tissue sample analysis. Specialty groups (surgery, radiology, pathology, clinical oncology, medical oncology, clinical nurse specialists and anaesthetics) have been established to provide oversight and direction for their clinical area within the programme, to review data and analysis and to develop appropriate educational initiatives. ETHICS AND DISSEMINATION: The YCR BCIP is aiming to address the variation in practice to significantly improve colorectal cancer outcomes across the Yorkshire and Humber region. PROMs and tissue sample collection and analysis will help to capture the information required to fully assess care in the region. Engagement of the region's MDTs with their data will lead to a range of educational initiatives, studies and clinical audits that aim to optimise practice across the region.


Subject(s)
Colorectal Neoplasms/therapy , Patient Care Team/organization & administration , Clinical Protocols , England , Humans , Patient Reported Outcome Measures , Quality Improvement , Quality of Life
3.
J Clin Pathol ; 72(6): 443-447, 2019 Jun.
Article in English | MEDLINE | ID: mdl-30723092

ABSTRACT

Colorectal cancer (CRC) is common with 3% of cases associated with germline mutations in the mismatch repair pathway characteristic of Lynch syndrome (LS). The UK National Institute for Health and Care Excellence recommends screening for LS in all patients newly diagnosed with CRC, irrespective of age. The Yorkshire Cancer Research Bowel Cancer Improvement Programme includes a regional LS screening service for all new diagnoses of CRC. In the first 829 cases screened, 80 cases showed deficient mismatch repair (dMMR) including four cases showing areas with loss of expression of all four mismatch repair proteins by immunohistochemistry. The cases demonstrated diffuse MLH1 loss associated with BRAF mutations and MLH1 promoter hypermethylation in keeping with sporadic dMMR, with presumed additional double hit mutations in MSH2+/-MSH6 rather than underlying LS. Recognition and accurate interpretation of this unusual phenotype is important to prevent unnecessary referrals to clinical genetics and associated patient anxiety.


Subject(s)
Biomarkers, Tumor , Colorectal Neoplasms/enzymology , Colorectal Neoplasms/genetics , DNA Methylation , DNA-Binding Proteins/analysis , MutL Protein Homolog 1/genetics , MutS Homolog 2 Protein/analysis , Promoter Regions, Genetic , Aged , Aged, 80 and over , Biomarkers, Tumor/analysis , Biomarkers, Tumor/genetics , Colorectal Neoplasms/pathology , DNA Mismatch Repair , Early Detection of Cancer/methods , England , Female , Genetic Predisposition to Disease , Humans , Immunohistochemistry , Male , Molecular Diagnostic Techniques , Mutation , Phenotype , Prognosis , Proto-Oncogene Proteins B-raf/genetics
4.
PLoS Pathog ; 11(2): e1004681, 2015 Feb.
Article in English | MEDLINE | ID: mdl-25710496

ABSTRACT

The neurotrophic tyrosine kinase receptor type 2 (Ntrk2, also known as TrkB) and its ligands brain derived neurotrophic factor (Bdnf), neurotrophin-4 (NT-4/5), and neurotrophin-3 (NT-3) are known primarily for their multiple effects on neuronal differentiation and survival. Here, we provide evidence that Ntrk2 plays a role in the pathologic remodeling of the spleen that accompanies chronic infection. We show that in Leishmania donovani-infected mice, Ntrk2 is aberrantly expressed on splenic endothelial cells and that new maturing blood vessels within the white pulp are intimately associated with F4/80(hi)CD11b(lo)CD11c(+) macrophages that express Bdnf and NT-4/5 and have pro-angiogenic potential in vitro. Furthermore, administration of the small molecule Ntrk2 antagonist ANA-12 to infected mice significantly inhibited white pulp neovascularization but had no effect on red pulp vascular remodeling. We believe this to be the first evidence of the Ntrk2/neurotrophin pathway driving pathogen-induced vascular remodeling in lymphoid tissue. These studies highlight the therapeutic potential of modulating this pathway to inhibit pathological angiogenesis.


Subject(s)
Leishmania donovani/pathogenicity , Leishmaniasis, Visceral/pathology , Membrane Glycoproteins/metabolism , Neovascularization, Physiologic/physiology , Protein-Tyrosine Kinases/metabolism , Spleen/blood supply , Animals , Azepines/pharmacology , Benzamides/pharmacology , Brain-Derived Neurotrophic Factor/biosynthesis , Cell Line , Endothelial Cells/metabolism , Female , Leishmaniasis, Visceral/parasitology , Macrophages/metabolism , Membrane Glycoproteins/antagonists & inhibitors , Mice , Mice, Inbred BALB C , Mice, Knockout , Protein-Tyrosine Kinases/antagonists & inhibitors , Receptors, Nerve Growth Factor/biosynthesis , Signal Transduction/physiology , Spleen/metabolism , Splenomegaly/parasitology , Splenomegaly/pathology
5.
Melanoma Res ; 21(1): 24-34, 2011 Feb.
Article in English | MEDLINE | ID: mdl-21164369

ABSTRACT

PAX3 and MITF are important transcriptional activators in the melanocyte lineage and PAX3 is thought to control MITF expression during normal melanocyte differentiation. However, it is not clear whether this is still true in melanoma and whether the effects of knockdown of PAX3 on the inhibition of melanoma growth or survival are by its regulation of MITF. By western blot and quantitative real-time reverse transcription-PCR, we investigated the relationship between PAX3 and MITF expression in 27 metastatic melanoma and one immortalized melanocyte cell lines. All lines were found to express both PAX3 and MITF proteins but levels varied by 15 fold and more than 100 fold, respectively. The expression of PAX3 protein was correlated with that of MITF (r=0.75; P<0.001) but the expression of PAX3 protein and MITF mRNA was not. Immunofluorescence microscopy showed that individual cells expressed widely differing relative amounts of PAX3 and MITF protein. By MTT cell proliferation and flow cytometry assays, both MITF and PAX3 proteins seemed to be functional, as knockdown with siRNA led to reduced proliferation and induction of apoptosis. However, knockdown of PAX3 with small interfering RNA did not decrease MITF expression and vice versa. In one cell line (NZM15), silencing of PAX3 induced terminal differentiation whereas silencing of MITF induced expression of FOXD3, a repressor of melanogenesis. The results suggest that the melanoma lines used in this study show considerable phenotypic variation of expression of these two transcriptional activators and reflect a deregulation of the developmental process operating in the genesis of the melanocyte lineage, and that they probably function independently to enhance the survival of melanoma cells.


Subject(s)
Gene Expression Regulation, Neoplastic , Gene Silencing , Melanoma/metabolism , Microphthalmia-Associated Transcription Factor/metabolism , Paired Box Transcription Factors/metabolism , Skin Neoplasms/metabolism , Apoptosis , Cell Differentiation , Cell Line, Tumor , Cell Proliferation , Cell Survival , Flow Cytometry , Humans , Melanocytes/metabolism , Neoplasm Metastasis , PAX3 Transcription Factor , Phenotype , RNA, Small Interfering/metabolism
6.
PLoS One ; 4(12): e8461, 2009 Dec 24.
Article in English | MEDLINE | ID: mdl-20041153

ABSTRACT

BACKGROUND: We are investigating the molecular basis of melanoma by defining genomic characteristics that correlate with tumour phenotype in a novel panel of metastatic melanoma cell lines. The aim of this study is to identify new prognostic markers and therapeutic targets that might aid clinical cancer diagnosis and management. PRINCIPAL FINDINGS: Global transcript profiling identified a signature featuring decreased expression of developmental and lineage specification genes including MITF, EDNRB, DCT, and TYR, and increased expression of genes involved in interaction with the extracellular environment, such as PLAUR, VCAN, and HIF1a. Migration assays showed that the gene signature correlated with the invasive potential of the cell lines, and external validation by using publicly available data indicated that tumours with the invasive gene signature were less melanocytic and may be more aggressive. The invasion signature could be detected in both primary and metastatic tumours suggesting that gene expression conferring increased invasive potential in melanoma may occur independently of tumour stage. CONCLUSIONS: Our data supports the hypothesis that differential developmental gene expression may drive invasive potential in metastatic melanoma, and that melanoma heterogeneity may be explained by the differing capacity of melanoma cells to both withstand decreased expression of lineage specification genes and to respond to the tumour microenvironment. The invasion signature may provide new possibilities for predicting which primary tumours are more likely to metastasize, and which metastatic tumours might show a more aggressive clinical course.


Subject(s)
Gene Expression Profiling , Melanoma/genetics , Melanoma/pathology , Skin Neoplasms/genetics , Skin Neoplasms/pathology , Cell Line, Tumor , Cell Movement/genetics , Gene Dosage/genetics , Gene Expression Regulation, Neoplastic , Genes, Neoplasm/genetics , Genome, Human/genetics , Humans , Models, Genetic , Neoplasm Invasiveness/genetics , Neoplasm Invasiveness/pathology , Neoplasm Metastasis , Neoplasm Proteins/genetics , Neoplasm Proteins/metabolism , Oligonucleotide Array Sequence Analysis , RNA, Messenger/genetics , RNA, Messenger/metabolism , Reproducibility of Results
7.
Reproduction ; 133(1): 11-9, 2007 Jan.
Article in English | MEDLINE | ID: mdl-17244728

ABSTRACT

Apoptosis plays a critical role in regulating sperm production. Removal of androgens and gonadotropins, or estrogen administration induces germ cell apoptosis. It is hypothesized that dietary phytoestrogens increase apoptosis of developing germ cells, decreasing sperm production. This study aimed to test this in rats fed a high phytoestrogen diet only during adulthood. Male Wistar rats used in this study were offspring of females maintained on a low phytoestrogen diet prior to conception through to weaning. After weaning, juveniles were fed the same low phytoestrogen diet into adulthood. A cohort of males were transferred to a high phytoestrogen diet for 24 days and subsequently testes were collected from all animals. In the high phytoestrogen fed group, homogenization-resistant sperm counts were significantly decreased, as were epididymal sperm counts. Morphometric analysis determined round and elongated spermatid volumes to be significantly decreased, but seminiferous tubule lumen diameters to be significantly increased. TUNEL analysis determined that apoptosis of spermatocytes and round spermatids was significantly greater in the high phytoestrogen fed rats. Neither plasma gonadotropin concentrations nor testicular testosterone were altered. In conclusion, exposure of the adult male rat to a high phytoestrogen diet disrupts spermatogenesis, increasing germ cell apoptosis. This effect is independent of the hypothalamo-pituitary-testicular axis and is likely due to disruption of estrogen's actions in the testis.


Subject(s)
Phytoestrogens/administration & dosage , Spermatogenesis/drug effects , Spermatozoa/cytology , Animal Feed , Animals , Apoptosis/drug effects , Gonadotropins, Pituitary/blood , In Situ Nick-End Labeling , Male , Meiosis , Rats , Rats, Wistar , Seminiferous Tubules/anatomy & histology , Sperm Count , Spermatozoa/drug effects , Testosterone/blood
SELECTION OF CITATIONS
SEARCH DETAIL
...